-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
assali hopes to double its five-year lung cancer survival rate by 2025. This is an ambitious goal because lung cancer is a disease that is the leading cause of cancer death in the United States.
But AstraZeneta is not going to go it alone. It is one of the four founding partners of the New Lung Ambition Alliance, which aims to address what happens in lung cancer by creating an ecosystem of awareness, screening, early diagnosis, support, and innovative research and treatment to improve survival rates.
In addition to UK drugmakers, the group is made up of a global group of physicians (International Lung Cancer Research Association), patient and patient advocates (Global Lung Cancer Alliance) and Diagnostics (Guardant Health), and although it is a different group, there are four projects with a common specific goal to address lung cancer.
Related: AstraZeneta's
Imfinzi
and Roche battle small cell lung cancerWe both believe that new developments are creating new possibilities for changing diagnosis, treatment and lung cancer management. We have reason to believe that the scientific advances we have made give us the opportunity to meaningfully influence lung cancer outcomes in a way that has not been discussed in the past," said David Fredrickson, Executive Vice President and Head of AZ's Global Oncology Business Unit.
He noted, however, that the work needed to go beyond science and research. To this end, the Alliance focuses on increasing efforts to improve lung cancer screening, while also working together to develop innovative drugs around the world. The third area the team is addressing is the quality of care for survivors, which will become increasingly necessary as survival rates increase and lung cancer becomes a chronic or cured disease.
Projects already under way by the Alliance cover a range of problem areas, including the use of technology to address barriers to extensive screening between countries, projects to address the importance of accurate phased phases, pathological response projects and the Lung Cancer Care Initiative, a pilot project that seeks submission from patient groups later this year.
Related:
nice
stops
az
's
Tagrisso
research and replaces it with Pfizer rival
VizimproOur goal at AstraZeneta is to eliminate cancer as the cause of death. We know that in order to be able to do that, partnerships will be taken. It's not just therapy, it's everything that wraps it up," Frederiksen said.
“ We know that when we see meaningful improvements in promoting overall survival in areas such as breast cancer and other HIV-related diseases, it starts with bringing together multidisciplinary groups around a common cause. We hope this will give us momentum," he added.
AstraZeneta refocused on oncology in 2014 and has since launched a range of new drugs, including Imfinzi, Calquence, Lynparza and Tagrisso. In the area of lung cancer, the PD-L1 drug Imfinzi was approved for the treatment of stage III lung cancer that could not be surgically removed, while Tagrisso was approved for the treatment of non-small cell lung cancer with EGFR mutations. (cyy123.com)